TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33169671
Drug: Adjunctive treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive treatments for refractory hypoxaemia
Study: 33170484
Drug: Pimasertib (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimasertib (dose range 1-255 mg/day)
Study: 33171487
Drug: Oral 5-azacytidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-azacytidine 300 mg once per day on days 1 to 14 and romidepsin 14 mg/m2 on days 8, 15, and 22 every 35 days
Study: 33171487
Drug: Oral 5-azacytidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-azacytidine and romidepsin
Study: 33172424
Drug: NTM-PD treatment
Normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTM-PD treatment (antibiotics)
Study: 33172444
Drug: Multivariable prediction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivariable prediction model based on 8 variables (age, race, insurance, GINI income inequality, long-term anticoagulant use, receipt of a flu vaccine in the past year, frequency of missed clinic appointments, and clinic site)
Study: 33172887
Drug: SARS-CoV-2 antibody
Normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 antibody testing
Study: 33173161
Drug: Low-dose ruxolitinib
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ruxolitinib plus steroid
Study: 33173916
Drug: Centhaquine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centhaquine (0.01 mg/kg) in 100 mL normal saline infusion over 1 hour
Study: 33173916
Drug: Control (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normal saline) in 100 mL infusion over 1 hour
Study: 33176023
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid prescribing
Study: 33176023
Drug: Treatment escalation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment escalation
Study: 33176074
Drug: Subanesthetic intravenous
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanesthetic intravenous ketamine combined with prolonged exposure therapy
Study: 33176443
Drug: Omecamtiv Mecarbil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv Mecarbil, dosage and duration not available
Study: 33176617
Drug: Single-capsule bismuth
Normalized name: bismuth subsalicylate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-capsule bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline, metronidazole), 3 capsules every 6 hours for 10 days
Study: 33176617
Drug: Single-capsule bismuth
Normalized name: bismuth subsalicylate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-capsule bismuth quadruple therapy (first-line treatment)
Study: 33176617
Drug: Single-capsule bismuth
Normalized name: bismuth subsalicylate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-capsule bismuth quadruple therapy (second-line treatment)
Study: 33176617
Drug: Single-capsule bismuth
Normalized name: bismuth subsalicylate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-capsule bismuth quadruple therapy (third to sixth line treatment)
Study: 33176617
Drug: Single-capsule bismuth
Normalized name: bismuth subsalicylate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-capsule bismuth quadruple therapy
Study: 33178636
Drug: E6011 (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 (humanized anti-FKN monoclonal antibody)
Study: 33179591
Drug: Solriamfetol 75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 75, 150, or 300 mg/day for ≤ 52 weeks
Study: 33179845
Drug: Long-acting glucagon-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting glucagon-like peptide-1 receptor agonists (LA GLP-1RAs)
Study: 33180026
Drug: Psychotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy alone (treatment-as-usual)
Study: 33180106
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of TKIs
Study: 33181832
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibrutinib, obinutuzumab, and venetoclax (venetoclax at 400 mg per day).
Study: 33181832
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibrutinib, obinutuzumab, and venetoclax.
Study: 33183506
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment impact during the pandemic
Study: 33184050
Drug: RhoC-derived 20mer
Approvals — FDA: no, EMA: no, PMDA: no
Description: RhoC-derived 20mer peptide vaccine (0.1 mg, subcutaneous injections every 2 weeks for the first 6 doses, then every 4 weeks for a total of 30 weeks)
Study: 33184050
Drug: RhoC-derived 20mer
Approvals — FDA: no, EMA: no, PMDA: no
Description: RhoC-derived 20mer peptide vaccine
Study: 33185490
Drug: Temporoparietal fascia
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporoparietal fascia over polypropylene implants
Study: 33186237
Drug: Edoxaban administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban administered via PEG
Study: 33186617
Drug: Combined external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined external beam radiation therapy (45 Gy in 25 fractions) and HDR brachytherapy (19 Gy in 2 fractions)
Study: 33186617
Drug: Combined external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined external beam radiation therapy and HDR brachytherapy
Study: 33187482
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (150-200 µg daily) during preconception, pregnancy, and lactation
Study: 33187482
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (150-200 µg daily)
Study: 33187482
Drug: Serum thyroid-hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum thyroid-hormone parameters in the 1st trimester of pregnancy
Study: 33188385
Drug: Azlocillin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azlocillin (100 mg/kg q8h)
Study: 33188413
Drug: Mode of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mode of delivery (C-section) with antibiotic exposure
Study: 33188873
Drug: Adjuvant gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant gemcitabine treatment (43 patients in monocentric cohort, 203 patients in multicentric cohort)
Study: 33189854
Drug: Gastric Electrical
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric Electrical Stimulation (Enterra therapy)
Study: 33190629
Drug: ≥50 mL/(kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥50 mL/(kg · day) human milk
Study: 33191112
Drug: Relebactam/imipenem/cilastatin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relebactam/imipenem/cilastatin (250 mg/500 mg/500 mg) dosed every 6 h for 5-14 days
Study: 33191169
Drug: Minimal residual
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal residual disease measurement and preemptive therapies
Study: 33191774
Drug: F/TDF at
Approvals — FDA: no, EMA: no, PMDA: no
Description: F/TDF at 33% of daily dosing
Study: 33191774
Drug: F/TDF at
Approvals — FDA: no, EMA: no, PMDA: no
Description: F/TDF at 67% of daily dosing
Study: 33191774
Drug: F/TDF at
Approvals — FDA: no, EMA: no, PMDA: no
Description: F/TDF at 100% of daily dosing
Study: 33192400
Drug: Medtronic Activa
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medtronic Activa PC+ S device stimulation in the supplementary motor area (SMA) and ventral capsule/ventral striatum (VC/VS)
Study: 33192504
Drug: Spironolactone, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone, dosage and duration not specified
Study: 33192504
Drug: Dry Extract,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Extract, dosage and duration not specified
Study: 33192706
Drug: RG7203 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7203 (two doses)
Study: 33195707
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (n = 147)
Study: 33195874
Drug: Higher frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher frequency point-of-care (POC) viral load (VL) and targeted drug resistance mutation (DRM) testing
Study: 33196449
Drug: Self-administered intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intervention with assistance via chat
Study: 33196449
Drug: Self-administered intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intervention without assistance via chat
Study: 33196581
Drug: DAPT discontinuation
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT discontinuation <6 months after PCI
Study: 33196581
Drug: Resuming or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resuming or starting cancer treatment (chemotherapy, radiation therapy, or surgery) after PCI
Study: 33196581
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of aspirin and early P2Y12 inhibitor discontinuation
Study: 33198671
Drug: Lenvatinib 24
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 24 mg orally once daily in 28-day cycles
Study: 33198674
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic chemotherapy, HIPEC and CRS (conversion therapy group)
Study: 33198674
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and HIPEC (palliative chemotherapy group)
Study: 33198674
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic chemotherapy and HIPEC
Study: 33198781
Drug: Lung cancer
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung cancer screening with baseline health questionnaire, spirometry, and low-dose CT scan.
Study: 33199917
Drug: Drug-target enrichment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-target enrichment analysis
Study: 33200217
Drug: Sirolimus (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (oral administration, dose-adjusted to maintain a therapeutic range of 6-15 ng/ml for 6 months)
Study: 33200217
Drug: Sirolimus (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (oral administration)
Study: 33201358
Drug: Liposomal irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal irinotecan 50 or 70 mg/m²
Study: 33201789
Drug: Subharmonic-aided pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subharmonic-aided pressure estimation (SHAPE) using a US contrast agent and saline infusion
Study: 33203317
Drug: Behaviour change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour change intervention to support memory and brain health, details on dosage and duration not available
Study: 33203645
Drug: Neratinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib at 240 mg/day with cetuximab (standard dosage)
Study: 33203645
Drug: Neratinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib at lower doses (120 mg, 160 mg, 200 mg) with cetuximab (standard dosage)
Study: 33203665
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg daily from day 1 plus nivolumab 3 mg/kg intravenously on day 15, then every 2 weeks (phase Ib)
Study: 33203665
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg for the first 14 days (induction) then 25 mg per day plus nivolumab on the same schedule (phase II)
Study: 33204764
Drug: Hydroxychloroquine (once-daily)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (once-daily)
Study: 33204764
Drug: Hydroxychloroquine (twice-weekly)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (twice-weekly)
Study: 33204764
Drug: Hydroxychloroquine (once-weekly)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (once-weekly)
Study: 33205032
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with bevacizumab (Group A) for cycles 3-6
Study: 33205032
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy without bevacizumab (Group B) for cycles 3-6
Study: 33205280
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication
Study: 33205510
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment with mechanical debridement plus systemic amoxicillin/metronidazole for 7 days
Study: 33206198
Drug: Botulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin-A injection alongside physical therapies
Study: 33206198
Drug: Botulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin-A injection
Study: 33206198
Drug: Therapy following
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy following botulinum toxin-A injection
Study: 33206198
Drug: Commercially-available botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially-available botulinum toxin-A agents
Study: 33207247
Drug: GDF-15 neutralization
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDF-15 neutralization with monoclonal antibody mAB1
Study: 33207247
Drug: Chemotherapy agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy agents with high clinical emetic score
Study: 33208134
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high physical work demands and high leg pain intensity
Study: 33208326
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAAs) treatment consisting of sofosbuvir and daclatasvir for 12 weeks, with ribavirin added in cases of cirrhosis.
Study: 33209056
Drug: Serratus anterior
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratus anterior plane block (SAPB) with 25 mL bupivacaine 0.25%
Study: 33209056
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 25 mL bupivacaine 0.25%
Study: 33209626
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy combined with immunotherapy (pembrolizumab)
Study: 33209626
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment strategies
Study: 33210217
Drug: Family-administered delirium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-administered delirium detection tools
Study: 33210276
Drug: Liraglutide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2 mg/day) as add-on therapy to metformin (1500-3000 mg/day) for 4 months
Study: 33210333
Drug: Vedolizumab Q8W
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab Q8W dosing
Study: 33211315
Drug: Pimasertib (28-255
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimasertib (28-255 mg/day)
Study: 33211842
Drug: Loncastuximab tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loncastuximab tesirine (ADCT-402) at doses ranging from 15 to 200 µg/kg, with a recommended dose of 150 µg/kg every 3 weeks for 2 doses followed by 75 µg/kg every 3 weeks.
Study: 33212251
Drug: Collection tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collection tube type (heparin vs Cell Save (CS) preservation tubes)
Study: 33212251
Drug: Treatment effect
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effect (pre- vs post-chemotherapy)
Study: 33214209
Drug: Inhaled TD139
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled TD139 (0.3-10 mg, once daily for 14 days)
Study: 33214209
Drug: Inhaled TD139
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled TD139 (0.15-50 mg, single doses)
Study: 33214615
Drug: Preemptive interferon-α
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive interferon-α (IFN-α) treatment
Study: 33214879
Drug: Telemedicine solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine solution for the post-anesthesia care unit
Study: 33215602
Drug: Rectal thermometer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal thermometer (REC)
Study: 33216238
Drug: Sufentanil sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil sublingual tablet system (SSTS) 15 mcg
Study: 33216238
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone extended release 10 mg twice daily and oral oxycodone immediate-release 5 mg up to four times daily on demand (Oxy group)
Study: 33216238
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (Oxy group)
Study: 33216287
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab (TCZ-SC) treatment
Study: 33216356
Drug: Nivolumab and
Normalized name: nivolumab and relatlimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab and ipilimumab (nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg intravenously every 3 weeks for 4 doses, followed by 480 mg of nivolumab intravenously every 4 weeks)
Study: 33216772
Drug: Serum apolipoprotein-A1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum apolipoprotein-A1 at 1.25 g/L cutoff
Study: 33217193
Drug: Any treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment for recurrence
Study: 33217357
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody treatment (mAB114 or REGN-EB3)
Study: 33218740
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa treatment
Study: 33219014
Drug: Talimogene laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Talimogene laherparepvec (TVEC) at dose level 1 (DL 1 = 10) combined with neoadjuvant chemotherapy (NAC)
Study: 33219014
Drug: Talimogene laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Talimogene laherparepvec (TVEC) at dose level 2 (DL 2) combined with neoadjuvant chemotherapy (NAC)
Study: 33221175
Drug: Telisotuzumab vedotin
Normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telisotuzumab vedotin 2.7 mg/kg administered intravenously every 3 weeks until disease progression or unacceptable toxicity
Study: 33221715
Drug: Bifrontal transcranial
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifrontal transcranial direct current stimulation (tDCS) applied using a 2 mA current for 20 min, twice daily, for 5 consecutive weekdays.
Study: 33222307
Drug: Frequent antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent antibiotic use
Study: 33222307
Drug: Higher nasal
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher nasal expression of IL-17 and T1R3 (sweet taste receptor)
Study: 33222379
Drug: Carbapenem monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbapenem monotherapy (primarily meropenem)
Study: 33222379
Drug: BLBLI monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLBLI monotherapy (mostly piperacillin-tazobactam)
Study: 33222379
Drug: Any active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any active therapy (including BLBLI and carbapenem)
Study: 33222803
Drug: Oral tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tenofovir disoproxil fumarate and emtricitabine for PrEP, taken daily for the first 12 weeks.
Study: 33224628
Drug: SAR439459 (pan-TGFβ
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR439459 (pan-TGFβ neutralizing antibody)
Study: 33224628
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SAR439459 with anti-PD-1
Study: 33224753
Drug: Rivaroxaban (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (once daily)
Study: 33224753
Drug: Dabigatran (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (twice daily)
Study: 33224806
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone (treatment group, n=41)